<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-RIL23483-Y88-M1-NT3"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 S3258 IS: ALS Better Care Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2023-11-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>118th CONGRESS</congress><session>1st Session</session><legis-num>S. 3258</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20231108">November 8, 2023</action-date><action-desc><sponsor name-id="S337">Mr. Coons</sponsor> (for himself and <cosponsor name-id="S288">Ms. Murkowski</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend title XVIII of the Social Security Act to provide coverage of ALS-related services under the Medicare program for individuals diagnosed with amyotrophic lateral sclerosis, and for other purposes.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="HCD5A05A92C9A4C60B1D9BD2EC8A15DA2"><section section-type="section-one" id="H3D4958D5B7704A24B886F90A535245AF"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>ALS Better Care Act</short-title></quote>.</text></section><section id="H7BCA2958281340B78B2C4D00AD76CAE9"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress makes the following findings:</text><paragraph id="H6BD47C9B59284144A60385F1566266AA"><enum>(1)</enum><text>Amyotrophic lateral sclerosis (in this section, referred to as <quote>ALS</quote>) is a progressive and debilitating neurodegenerative disease.</text></paragraph><paragraph id="HD3AABF52A053434A9E77A4B93C1FEFD5"><enum>(2)</enum><text>Key services, that include (but are not limited to) providing specialized physician or nurse practitioner support, occupational therapy support, speech pathology support, physical therapy, dietary support, respiratory support, registered nurse support, and coordination of the furnishing of durable medical equipment, are crucial for managing the complex medical needs of ALS patients.</text></paragraph><paragraph id="H4AF7392CC8D14F84BF5987D26DDDDDE1"><enum>(3)</enum><text>Studies have shown ALS clinics that provide these key services to ALS patients extend these patients’ lifespans and improve the quality of their lives.</text></paragraph><paragraph id="HC9E032B32FF6427EAFD2F3F129A7825C"><enum>(4)</enum><text>These key services are furnished by a range of healthcare professionals.</text></paragraph><paragraph id="HCB065B7DFE8D4E1D85E66BEB2BA842F8"><enum>(5)</enum><text>Facilities providing care to ALS patients currently face inadequate Medicare reimbursement for the key services they offer to these patients.</text></paragraph><paragraph id="HA09305EBDED44464B4AA3191CDE43D1C"><enum>(6)</enum><text>Insufficient reimbursement creates significant challenges for facilities specializing in ALS care, resulting in extended wait times for patients in need of crucial services and hampering the ability of these facilities to innovate and improve the quality of care provided to ALS patients.</text></paragraph><paragraph id="HD327E5A69D1C431F94947B9A395E37F0"><enum>(7)</enum><text>Improved reimbursement rates would encourage facilities to invest in research, innovation, and technology, leading to enhanced treatment options for ALS and improved patient outcomes.</text></paragraph><paragraph id="H275CC368C4014251BC675080B218E96C"><enum>(8)</enum><text>Remote medical management options for individuals suffering from ALS must be an essential part of access to care for such individuals, especially those living in rural areas or care deserts.</text></paragraph><paragraph id="HA846881CE5514950816F1C8D55DFBD3A"><enum>(9)</enum><text>Telehealth is one of the essential management options referred to in paragraph (8) and can assist in delivering timely and comprehensive care, as ALS patients living in rural areas or care deserts often face challenges in accessing specialized ALS care and could otherwise be required to travel long travel distances, often with caregivers or family members.</text></paragraph><paragraph id="HA81F9E99E537414D9D50A70DAFA80A82"><enum>(10)</enum><text>Telehealth is especially important in maintaining access to care for ALS patients as the disease progresses and causes ALS patients to have more limited mobility, which may make it challenging to attend in-person appointments regularly.</text></paragraph><paragraph id="H2AF9AC9F5C454E738EECD39ECC24B33C"><enum>(11)</enum><text>Low funding and difficulty in staffing for ALS clinical trials delay the development and availability of potential treatments and therapies for individuals living with the disease.</text></paragraph><paragraph id="HFAD9661081D4417FAE1E6E791097AF22"><enum>(12)</enum><text>Inadequate funding for ALS clinical trials also impedes the ability to attract and retain qualified researchers, clinicians, and support staff, limiting the overall progress and success of these trials.</text></paragraph></section><section id="H8EDB96DBE9E04FEC923B7581D6027560"><enum>3.</enum><header>Providing for coverage of ALS-related services under the Medicare program for individuals diagnosed with amyotrophic lateral sclerosis</header><subsection id="HEFBD2A6C00A34B21AF49569E7E832904"><enum>(a)</enum><header>In general</header><text>Part E of title XVIII of the Social Security Act (42 U.S.C. 1395 et. seq.) is amended by inserting after section 1881A the following new section:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H7B889370E82D483D9720FFE1DC23F4B3"><section id="H517038706D3046BEB6CE6CB6FEA19E1E"><enum>1881B.</enum><header>Medicare coverage of ALS-related services for individuals diagnosed with amyotrophic lateral sclerosis</header><subsection id="HDAD7578DCA9E4936B75DA82E0BECC866"><enum>(a)</enum><header>In general</header><text>In the case of a covered ALS individual, the Secretary shall establish a supplemental facility-based payment system described in subsection (d) for ALS-related services provided to such an individual.</text></subsection><subsection id="H789048C31503491FAE942F788AB1FCC1"><enum>(b)</enum><header>Covered ALS individual</header><text>For purposes of this section, the term <term>covered ALS individual</term> means an individual who is medically determined to have amyotrophic lateral sclerosis (as described in section 226(h)).</text></subsection><subsection id="H8DB79900FA8640489B774021E0892A39"><enum>(c)</enum><header>ALS-Related services</header><text>For purposes of this section, the term <term>ALS-related services</term> means items and services that are furnished to a covered ALS individual in an outpatient setting by a qualified provider (or by others under arrangements with them made by the qualified provider) for the care and treatment of such an individual with respect to the progression of amyotrophic lateral sclerosis.</text></subsection><subsection id="HF6014B771FEA4E7C82A639A92C5BE545"><enum>(d)</enum><header>Payment system</header><paragraph id="H9009ED2B9CD9446DB95FB189AD574175"><enum>(1)</enum><header>Authority</header><text display-inline="yes-display-inline">The Secretary shall establish a payment system under which a single payment determined in accordance with the succeeding paragraphs is made to a qualified provider for ALS-related services furnished to a covered ALS individual during a visit beginning on or after January 1, 2025, for the purpose of reimbursing the qualified provider for furnishing ALS-related services.</text></paragraph><paragraph id="H662C57D6F10249E1B2AD3869380CCC5B"><enum>(2)</enum><header>Base payment amount</header><subparagraph id="HFAD495C7824D456696121821CF267431"><enum>(A)</enum><header>2025</header><text>For coverage year 2025, the Secretary shall establish a single payment amount for ALS-related services equal to $800 for such services furnished for each visit during such year.</text></subparagraph><subparagraph id="H03293F613CF7437CA7F1503C82ABF0F1"><enum>(B)</enum><header>2026</header><text display-inline="yes-display-inline">For coverage year 2026, the Secretary shall establish a single payment amount for ALS-related services furnished for each visit during such year that is the greater of—</text><clause id="HB2366B914BC449A7BF7D47516B8DBFD3"><enum>(i)</enum><text>the payment amount recommended by the Comptroller General in the report described in subparagraph (D); or</text></clause><clause id="HC5C9F275B18A4346864B1FCBAF4096B9"><enum>(ii)</enum><text>the amount specified in subparagraph (A).</text></clause></subparagraph><subparagraph id="H352371F39ECF4350A3155C5D37C6E1B0"><enum>(C)</enum><header>Subsequent years</header><text>The Secretary shall do each of the following:</text><clause id="HB256212AAD614D32A915552A2A6BBB36"><enum>(i)</enum><header>Annual increase</header><text>For each coverage year beginning with coverage year 2027, the Secretary shall annually increase the payment amount for each visit determined under this paragraph by an ALS services market basket percentage increase (as determined by the Secretary) for the purpose of reflecting the year-to-year changes in the prices of an appropriate mix of goods and services that are ALS-related services.</text></clause><clause id="HB9FDEAF7AB23463FAC19B40D223F83F5"><enum>(ii)</enum><header>Reestablishment of amount</header><text>For each coverage year beginning with coverage year 2028, and every 3 coverage years thereafter, for the purpose of ensuring that the range of ALS-related services is modernized over time, the Secretary shall reestablish a single payment amount for ALS-related services furnished for each visit during such year that is the greater of—</text><subclause id="HFA45601424324A56B339B1FEC8E1D2AC"><enum>(I)</enum><text>the payment amount recommended by the Comptroller General in the report described in clause (i) or (ii) of subparagraph (E), as applicable; or</text></subclause><subclause id="H973B54BC7F2746DD9E2314844351E098"><enum>(II)</enum><text>the payment amount specified pursuant to clause (i).</text></subclause></clause></subparagraph><subparagraph id="HB6BB3B08321F4C12BFCD63D1A38FEE61"><enum>(D)</enum><header>Report by the comptroller general</header><text display-inline="yes-display-inline">Not later than January 1, 2025, the Comptroller General shall, in consultation with qualified providers that are representative of the types of qualified providers eligible for payment under this subsection, submit to the Secretary of Health and Human Services a report that recommends a single payment amount for ALS-related services that takes into account the average amount of payment for each item or service included in ALS-related services that the Comptroller General estimates would have been payable—</text><clause id="HA05651D325894012AAAC6BE6251170A1"><enum>(i)</enum><text>under this title for such a service based on per patient utilization data from whichever single coverage year from 2021 through 2023 has the highest per patient utilization of ALS-related services, even if such service is not payable for a particular ALS individual because of the application of section 1862(a)(1)(A) with respect to an item or service provided to such individual;</text></clause><clause id="H5C6E7107251C475097FB6D01E9D72FA4"><enum>(ii)</enum><text>in the case that an estimate is unable to be determined pursuant to clause (i), by health insurance issuers and group health plans (as such terms are defined in section 2791 of the Public Health Service Act) and MA plans under part C for such a service, based on such data from whichever single coverage year from 2021 through 2023 has the highest per patient utilization of ALS-related services; and</text></clause><clause id="HE68FD70C41A14DB697DCB2FFFE52061F"><enum>(iii)</enum><text>in the case that an estimate is unable to be determined pursuant to clause (ii), based on the recommendation of the Specialty Society Relative Value Scale Update Committee of the American Medical Association or the estimate of the Comptroller General for such a service.</text></clause></subparagraph><subparagraph id="H65A19067228442CCB1DECBF5849156DA"><enum>(E)</enum><header>Subsequent reports</header><text>For the purpose of subparagraph (C)(ii)(I), the Comptroller General shall, not later than—</text><clause id="H16B256B22B7B44CAA757F02FE170C28C"><enum>(i)</enum><text>January 1, 2028, submit a report to the Secretary in accordance with subparagraph (D), except such subparagraph shall be applied by substituting <quote>2024 through 2026</quote> for <quote>2021 through 2023</quote> each place it appears; and</text></clause><clause id="H833F703A51E3402AA5F2156D3473B195"><enum>(ii)</enum><text>January 1, 2031, and every 3 years thereafter, submit a report to the Secretary in accordance with subparagraph (D), after application of clause (i), except clause (i) shall be applied by substituting coverage years that are 3 years later than the coverage years previously applicable for reports under clause (i) or this clause for <quote>2024 through 2026</quote>.</text></clause></subparagraph></paragraph><paragraph id="H9BFDDAB0CB3941A1BE8BA8194C7561F0"><enum>(3)</enum><header>Payment adjustments</header><text display-inline="yes-display-inline">The payment system under this subsection shall include a payment adjustment—</text><subparagraph id="H91F96EFB7D9A4971B570804F0F5BBB4B"><enum>(A)</enum><text>for a qualified provider that is participating in at least 1 clinical trial identified on the clinicaltrials.gov database (or any successor database) of the National Institutes of Health to account for the increased costs borne by such a qualified provider during such a clinical trial; and</text></subparagraph><subparagraph id="H3F6BF463950C47338756585F489AD75E"><enum>(B)</enum><text>to account for a medical service or technology that is furnished as a part of ALS-related services for which, as determined by the Secretary—</text><clause id="H81FCB54F73604858B993583837D4C512"><enum>(i)</enum><text>payment for the service or technology as part of ALS-related services under this section was not being made in the preceding coverage year; and</text></clause><clause id="H2AB11BC35A054BA7AD522345858E3503"><enum>(ii)</enum><text>the cost of the service or technology is not insignificant in relation to the payment amount (as determined under this subsection) payable for ALS-related services.</text></clause></subparagraph></paragraph><paragraph id="HF1411ED46D2E42BE9F858AEF1D7CC77A"><enum>(4)</enum><header>Mechanism for payments</header><text>For purposes of making payments for ALS-related services, the Secretary shall establish a mechanism under the payment system under this subsection which makes payment when a qualified provider submits a claim for reimbursement which includes, with respect to a covered ALS individual, an alphanumeric code issued under the International Classification of Diseases, 10th Revision, Clinical Modification (commonly referred to as <quote>ICD–10–CM</quote>) and its subsequent revisions that is for the treatment of a diagnosis of amyotrophic lateral sclerosis.</text></paragraph><paragraph id="HA839D2307FF44737BFC037E7E09CE14A"><enum>(5)</enum><header>No cost sharing</header><text>Payment under this subsection shall be made only on an assignment-related basis without any cost sharing.</text></paragraph><paragraph id="H5FC6244C8C7E4F9D90D141541EC91806"><enum>(6)</enum><header>Qualified provider defined</header><text display-inline="yes-display-inline">In this section, the term <term>qualified provider</term> means a provider of services or a clinic which—</text><subparagraph id="H52DC2DA8E9F94DCCAF0C8E36967EC94B"><enum>(A)</enum><text>is capable of furnishing care to a covered ALS individual, including by providing such services as providing specialized physician or nurse practitioner support, occupational therapy support, speech pathology support, physical therapy, dietary support, respiratory support, registered nurse support, and coordination of the furnishing of durable medical equipment; and</text></subparagraph><subparagraph id="H300D9C5C2D5B4F4DAC9101FEF1399717"><enum>(B)</enum><text>meets such requirements as the Secretary may prescribe by regulation to implement subparagraph (A), in consultation with—</text><clause id="H535FA1DEF2CD47529ED5F73400F8FF7C"><enum>(i)</enum><text>covered ALS individuals and their representatives;</text></clause><clause id="HA8AD4DAF9FFA47D5B98F66F6DDE0832C"><enum>(ii)</enum><text>physicians who provide ALS-related services and their representatives; and</text></clause><clause id="H52A11AFF96F24FC299525CE4A247E8E2"><enum>(iii)</enum><text>professional and non-profit organizations with expertise in amyotrophic lateral sclerosis.</text></clause></subparagraph></paragraph></subsection><subsection id="HDE02BED603CD4C8E8060F3FED4327321"><enum>(e)</enum><header>Clarification</header><text>Payment under subsection (d) shall be in addition to, and shall not supplant, any payment that would be otherwise made to a provider of services, physician, practitioner, supplier, or laboratory under any other provision of this title for an item or service furnished to a covered ALS individual.</text></subsection><subsection id="HAB3EF84348FD445BB99A6892B7F35040"><enum>(f)</enum><header>Implementation</header><paragraph id="H7CC0C8B57CBA4C3DB999C2FB133F6966"><enum>(1)</enum><header>In general</header><text>Except as provided under paragraph (2), the Secretary may implement the provisions of this section by program instruction or otherwise.</text></paragraph><paragraph id="HBEDCE8C83378435486A270821C9F6CBE"><enum>(2)</enum><header>Rulemaking</header><text>The Secretary shall implement subsections (c) and (d)(6) through notice and comment rulemaking.</text></paragraph></subsection><subsection id="HD13A57C9E53542B9B1DF70A01ADE9956"><enum>(g)</enum><header>Funding</header><text>For purposes of carrying out this section and subject to subsection (e), payment under this section shall be made from the Federal Supplementary Medical Insurance Trust Fund under section 1841 or from the Federal Hospital Insurance Trust Fund under section 1817.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H318DDC27230B4C92915F48B64862DD35"><enum>(b)</enum><header>Conforming amendments</header><paragraph id="H0B0679495C5A4B66BF721B1611C268E6"><enum>(1)</enum><header>Ensuring supplemental payments for ALS-related services</header><text>Section 1833(t) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395">42 U.S.C. 1395(t)</external-xref> is amended by adding at the end the following new paragraph:</text><quoted-block style="OLC" id="HEA8F09C4C89E4A6FABF2C441EFC305F3"><paragraph id="H9419073FF85B46EEAE2446684393FA54"><enum>(23)</enum><header>Ensuring supplemental payments for ALS-related services</header><text>Any covered OPD service furnished to a covered ALS individual (as defined in section 1881B(b)) that is otherwise payable to a qualified provider (as defined in section 1881B(d)(6)) pursuant to paragraph (4) shall be payable under such paragraph notwithstanding any payment made under section 1881B(d).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="HA6AB0538092E4E6C9789D43898B72AC7"><enum>(2)</enum><header>Definition of <quote>arrangements</quote></header><text>Section 1861(w)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(w)(1)</external-xref>) is amended by inserting <quote>qualified provider (as defined in section 1881B(d)(6)) with respect to ALS-related services (as defined in section 1881B(c)),</quote> before <quote>or hospice program</quote>.</text></paragraph></subsection></section><section id="HD124CA4E736E4B6D9A0BB4A68305315C"><enum>4.</enum><header>Report on challenges with respect to the administration and staffing of amyotrophic lateral sclerosis clinical trials</header><text display-inline="no-display-inline">Not later than 90 days after the date of the enactment of this Act, the Secretary of Health and Human Services, acting through the Director of the National Institute of Neurological Disorders and Stroke, shall submit to Congress and publish on the Internet website of the agency a report that identifies—</text><paragraph id="H448AF3F232004D7BBF5CD9F36EADB33D"><enum>(1)</enum><text>any challenges with respect to the administration and staffing of clinical trials for the prevention, diagnosis, mitigation, treatment, or cure of amyotrophic lateral sclerosis;</text></paragraph><paragraph id="H76F0BA5144094B9BA0E9282BC3F54655"><enum>(2)</enum><text>actions that the Director of the National Institute of Neurological Disorders and Stroke will take to address such challenges; and</text></paragraph><paragraph id="H483984E486994240A7B7742CCE5CED91"><enum>(3)</enum><text>any legislative recommendations (including requests for appropriations) to further improve the administration of such clinical trials.</text></paragraph></section></legis-body></bill> 

